


What is claimed is:

1. A combination therapy comprising at least one HER2-targeted STING agonist antibody-drug conjugate and at least one HER2-targeted therapy or at least one immunotherapy, wherein the HER2-targeted STING agonist antibody-drug conjugate is a conjugate of Formula (A):




wherein the conjugate comprises a HER2 antibody comprising a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence FTFSSYSMN (SEQ ID NO: 5); a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence YISSSSSTIYYADSVKG (SEQ ID NO: 6); a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GGHGYFDL (SEQ ID NO: 7); and a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence RASQSVSSSYLA (SEQ ID NO: 12); a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence GASSRAT (SEQ ID NO: 13); and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYHHSPILT (SEQ ID NO: 14), and d_{15} is about 8.

2. Use of at least one HER2-targeted STING agonist antibody drug conjugate in the manufacture of a medicament to treat, prevent, delay the progression of or otherwise ameliorate a symptom of a cancer, wherein the HER2-targeted STING agonist antibody-drug conjugate is to

be administered in combination with at least one HER2-targeted therapy or at least one immunotherapy,

wherein the HER2-targeted STING agonist antibody-drug conjugate is a conjugate of Formula (A):




wherein the conjugate comprises a HER2 antibody comprising a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence FTFSSYSMN (SEQ ID NO: 5); a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence YISSSSSTIYYADSVKG (SEQ ID NO: 6); a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GGHGYFDL (SEQ ID NO: 7); and a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence RASQSVSSSYLA (SEQ ID NO: 12); a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence GASSRAT (SEQ ID NO: 13); and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYHHSPLT (SEQ ID NO: 14), and d_{15} is about 8.

3. Use of at least one HER2-targeted therapy or at least one immunotherapy in the manufacture of a medicament to treat, prevent, delay the progression of or otherwise ameliorate a symptom of a cancer, wherein the at least one HER2-targeted therapy or at least one immunotherapy is to be administered in combination with at least one HER2-targeted STING

agonist antibody-drug conjugate,


wherein the HER2-targeted STING agonist antibody-drug conjugate is a conjugate of Formula (A):



wherein the conjugate comprises a HER2 antibody comprising a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence FTFSSYSMN (SEQ ID NO: 5); a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence YISSSSSTIYYADSVKG (SEQ ID NO: 6); a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GGHGYFDL (SEQ ID NO: 7); and a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence RASQSVSSSYLA (SEQ ID NO: 12); a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence GASSRAT (SEQ ID NO: 13); and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYHHSPILT (SEQ ID NO: 14), and d_{15} is about 8.

4. Use of at least one HER2-targeted STING agonist antibody-drug conjugate, and at least one HER2-targeted therapy or at least one immunotherapy in the manufacture of a medicament to treat, prevent, delay the progression of or otherwise ameliorate a symptom of a cancer,

wherein the HER2-targeted STING agonist antibody-drug conjugate is a conjugate of Formula (A):



wherein the conjugate comprises a HER2 antibody comprising a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence FTFSSYSMN (SEQ ID NO: 5); a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence YISSSSSTIYYADSVKG (SEQ ID NO: 6); a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GGHGYFDL (SEQ ID NO: 7); and a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence RASQSVSSSYLA (SEQ ID NO: 12); a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence GASSRAT (SEQ ID NO: 13); and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYHHSPLT (SEQ ID NO: 14), and d_{15} is about 8.

5. The combination of claim 1 or the use of any one of claims 2-4, wherein the HER2 antibody specifically binds to an epitope of the human HER2 receptor that includes residues 452 to 531 of the extracellular domain of the human HER2 receptor, residues 474 to 553 of SEQ ID NO: 1 or residues 452 to 531 of SEQ ID NO: 16.

6. The combination of claim 1, comprising at least one HER2-targeted STING agonist antibody-drug conjugate and at least one HER2-targeted therapy.

7. The use of any one of claims 2-4, wherein the at least one HER2-targeted STING agonist antibody-drug conjugate is administered in combination with the at least one HER2-targeted therapy.
8. The combination of claim 1, comprising at least one HER2-targeted STING agonist antibody-drug conjugate and at least one immunotherapy.
9. The use of any one of claims 2-4, wherein at least one HER2-targeted STING agonist antibody-drug conjugate is administered in combination with the at least one immunotherapy.
10. The combination of claim 1 or the use of any one of claims 2-4, wherein the HER2-targeted STING agonist antibody-drug conjugate enhances the efficacy of the HER2-targeted therapy or the immunotherapy.
11. The combination of claim 6 or use of claim 7, wherein the HER2-targeted therapy is an antibody or antigen binding fragment thereof that specifically binds HER2, a HER2-targeted antibody-drug conjugate that specifically binds HER2 or a small molecule inhibitor of HER2.
12. The combination or use of claim 11, wherein the antibody or antigen binding fragment thereof that specifically binds HER2 is a HER2 antibody, a HER2 dimerization inhibitor antibody or a combination thereof.
13. The combination or use of claim 12, wherein the HER2 antibody or the HER2 dimerization inhibitor antibody is trastuzumab, pertuzumab or margetuximab or biosimilars thereof.
14. The combination or use of claim 11, wherein HER2-targeted therapy is trastuzumab, pertuzumab, a combination of trastuzumab and pertuzumab, margetuximab, a biosimilar of trastuzumab, a biosimilar of pertuzumab, a combination of a biosimilar of trastuzumab and a biosimilar of pertuzumab, or a biosimilar of margetuximab.

15. The combination or use of claim 11, wherein the HER2-targeted antibody-drug conjugate that specifically binds HER2 is ado-trastuzumab emtansine (T-DM1) or fam-trastuzumab deruxtecan (trastuzumab deruxtecan).
16. The combination or use of claim 11, where the small molecule inhibitor of HER2 is tucatinib, neratinib or lapatinib.
17. The combination of claim 8 or the use of claim 9, wherein the immunotherapy is an immune checkpoint inhibitor.
18. The combination or the use of claim 17, wherein the immune checkpoint inhibitor is a monoclonal antibody, a humanized antibody, a fully human antibody, a fusion protein or a combination thereof.
19. The combination or the use of claim 17, wherein the immune checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor.
20. The combination or the use of claim 19, wherein the PD-1 inhibitor or the PD-L1 inhibitor is avelumab, durvalumab, dostarlimab, pembrolizumab, cemiplimab, nivolumab, or atezolizumab.
21. The use of any one of claims 2-5, 7, and 9-20, wherein the cancer is anal cancer, astrocytoma, leukemia, lymphoma, head and neck cancer, liver cancer, testicular cancer, cervical cancer, sarcoma, hemangioma, esophageal cancer, eye cancer, laryngeal cancer, mouth cancer, mesothelioma, skin cancer, myeloma, oral cancer, rectal cancer, colorectal cancer, throat cancer, bladder cancer, breast cancer, urothelial cancer, uterine cancer, ovarian cancer, prostate cancer, lung cancer, non-small cell lung cancer (NSCLC), colon cancer, pancreatic cancer, renal cancer, gastric cancer or gastric esophagogastric junction cancer.

22. The use of claim 21, wherein the cancer is breast cancer, gastric cancer, gastric esophagogastric junction cancer, colorectal cancer or non-small cell lung cancer.
23. The use of any one of claims 2-5, 7, and 9-20, wherein:
- i) the HER2-targeted STING agonist antibody-drug conjugate and the HER2-targeted therapy or the immunotherapy are administered simultaneously;
 - ii) the HER2-targeted STING agonist antibody-drug conjugate and the HER2-targeted therapy or the immunotherapy are administered sequentially in either order or in alternation;
 - iii) the HER2-targeted STING agonist antibody-drug conjugate is administered prior to the HER2-targeted therapy or the immunotherapy; or
 - iv) the HER2-targeted STING agonist antibody-drug conjugate is administered after the HER2-targeted therapy or the immunotherapy.